BR112018002406A2 - anticorpos que neutralizam potentemente o vírus da hepatite b e usos dos mesmos - Google Patents
anticorpos que neutralizam potentemente o vírus da hepatite b e usos dos mesmosInfo
- Publication number
- BR112018002406A2 BR112018002406A2 BR112018002406-6A BR112018002406A BR112018002406A2 BR 112018002406 A2 BR112018002406 A2 BR 112018002406A2 BR 112018002406 A BR112018002406 A BR 112018002406A BR 112018002406 A2 BR112018002406 A2 BR 112018002406A2
- Authority
- BR
- Brazil
- Prior art keywords
- hepatitis
- antibodies
- virus
- relates
- bind
- Prior art date
Links
- 241000700721 Hepatitis B virus Species 0.000 title abstract 2
- 208000006454 hepatitis Diseases 0.000 abstract 3
- 231100000283 hepatitis Toxicity 0.000 abstract 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 241000724709 Hepatitis delta virus Species 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
a presente invenção refere-se a anticorpos, e fragmentos de ligação a antígeno dos mesmos, os quais se ligam à região da alça antigênica do antígeno na superfície de hepatite b (hbsag) e neutralizam potencialmente a infecção tanto pelo vírus da hepatite b (hbv) como o vírus da hepatite delta (hdv). a invenção também se refere a epítopos aos quais os anticorpos e fragmentos de ligação a antígeno se ligam, bem como a ácidos nucleicos que codificam e células que produzem estes anticorpos e fragmentos de anticorpos. além disso, a invenção se refere ao uso dos anticorpos e fragmentos de anticorpo da invenção no diagnóstico, profilaxia e tratamento de hepatite b e hepatite d.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2015/001970 WO2017059878A1 (en) | 2015-10-07 | 2015-10-07 | Antibodies that potently neutralize hepatitis b virus and uses thereof |
| EPPCT/EP2015/001970 | 2015-10-07 | ||
| PCT/EP2016/074114 WO2017060504A1 (en) | 2015-10-07 | 2016-10-07 | Antibodies that potently neutralize hepatitis b virus and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018002406A2 true BR112018002406A2 (pt) | 2018-09-18 |
Family
ID=54330711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018002406-6A BR112018002406A2 (pt) | 2015-10-07 | 2016-10-07 | anticorpos que neutralizam potentemente o vírus da hepatite b e usos dos mesmos |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US10683344B2 (pt) |
| EP (2) | EP3359564B1 (pt) |
| JP (3) | JP6869968B2 (pt) |
| KR (1) | KR20180056777A (pt) |
| CN (3) | CN114539392B (pt) |
| AU (1) | AU2016334735B2 (pt) |
| BR (1) | BR112018002406A2 (pt) |
| CA (1) | CA2993745A1 (pt) |
| CY (1) | CY1123462T1 (pt) |
| DK (1) | DK3359564T3 (pt) |
| EA (1) | EA038301B1 (pt) |
| ES (1) | ES2813927T3 (pt) |
| HK (1) | HK1256869A1 (pt) |
| HR (1) | HRP20201345T1 (pt) |
| HU (1) | HUE050231T2 (pt) |
| IL (1) | IL258326B (pt) |
| LT (1) | LT3359564T (pt) |
| MX (1) | MX2018004127A (pt) |
| MY (1) | MY187161A (pt) |
| PH (1) | PH12018500199A1 (pt) |
| PL (1) | PL3359564T3 (pt) |
| PT (1) | PT3359564T (pt) |
| SI (1) | SI3359564T1 (pt) |
| WO (2) | WO2017059878A1 (pt) |
| ZA (1) | ZA201800710B (pt) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017059878A1 (en) * | 2015-10-07 | 2017-04-13 | Humabs Biomed Sa | Antibodies that potently neutralize hepatitis b virus and uses thereof |
| WO2019217654A1 (en) * | 2018-05-10 | 2019-11-14 | Walsh Renae | Methods and compositions for the treatment of hepatitis b infection |
| WO2019222506A1 (en) * | 2018-05-16 | 2019-11-21 | Chang Gung Memorial Hospital, Linkou | Novel leucine-rich repeat neuronal protein 1 (lrrn1) antibodies and uses thereof |
| US11932681B2 (en) | 2018-05-31 | 2024-03-19 | Novartis Ag | Hepatitis B antibodies |
| US20220127336A1 (en) * | 2018-12-19 | 2022-04-28 | Humabs Biomed Sa | Antibodies that neutralize hepatitis b virus and uses thereof |
| WO2020132346A1 (en) * | 2018-12-20 | 2020-06-25 | Vir Biotechnology, Inc. | Combination hbv therapy |
| KR102084912B1 (ko) * | 2019-01-17 | 2020-03-05 | 주식회사 녹십자 | B형 간염 바이러스 표면 항원의 입체 에피토프 및 이에 특이적으로 결합하는 항체 |
| CN114174332A (zh) * | 2019-07-20 | 2022-03-11 | 华辉安健（北京）生物科技有限公司 | 通过使用抗pre-S1 HBV抗体治疗HBV感染的方法 |
| KR20220063188A (ko) * | 2019-08-29 | 2022-05-17 | 비르 바이오테크놀로지, 인코포레이티드 | B형 간염 바이러스 감염을 치료하기 위한 항체 조성물 및 방법 |
| CN113717283B (zh) * | 2020-05-25 | 2023-05-26 | 厦门万泰凯瑞生物技术有限公司 | 一种抗乙型肝炎病毒e抗原的单克隆抗体及其应用 |
| AU2021296848A1 (en) | 2020-06-24 | 2023-02-09 | Humabs Biomed Sa | Engineered hepatitis B virus neutralizing antibodies and uses thereof |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| TW202245838A (zh) | 2021-01-26 | 2022-12-01 | 美商維爾生物科技股份有限公司 | 用於治療b型肝炎病毒感染的組成物及方法 |
| CN113234144B (zh) * | 2021-05-26 | 2022-02-25 | 武汉工程大学 | 一种人源性抗乙肝表面抗原的单链抗体、制剂、编码基因、载体质粒及宿主细胞 |
| WO2023287352A2 (en) * | 2021-07-15 | 2023-01-19 | National University Of Singapore | Anti-hbv antibodies and uses thereof |
| CN113777312B (zh) * | 2021-09-03 | 2024-02-02 | 普十生物科技(北京)有限公司 | 乙肝抗体片段的制备方法、乙肝抗体片段、试剂盒及应用 |
| WO2023039243A2 (en) * | 2021-09-13 | 2023-03-16 | Achelois Biopharma, Inc. | Hepatitis b virus antivirus (hbv-antivirus) compositions and methods of use |
| WO2023122555A2 (en) * | 2021-12-21 | 2023-06-29 | Hbvtech, Llc. | Methods for eliminating hepatitis b virus cccdna and rcdna and the hepatitis b drugs used in the methods thereof |
| TW202411246A (zh) | 2022-05-23 | 2024-03-16 | 美商維爾生物科技股份有限公司 | 經工程化之b型肝炎病毒中和抗體及其用途 |
| CN116162153A (zh) * | 2022-09-01 | 2023-05-26 | 复旦大学附属中山医院 | 一种乙肝病毒表面抗原的单克隆抗体及其应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3766162A (en) | 1971-08-24 | 1973-10-16 | Hoffmann La Roche | Barbituric acid antigens and antibodies specific therefor |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4233402A (en) | 1978-04-05 | 1980-11-11 | Syva Company | Reagents and method employing channeling |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| EP0906337A2 (en) | 1996-04-18 | 1999-04-07 | Abbott Laboratories | AN ANTIGENIC EPITOPE OF THE u A /u DETERMINANT OF HEPATITIS B SURFACE ANTIGEN AND USES THEREOF |
| GB9608626D0 (en) * | 1996-04-25 | 1996-07-03 | Univ College Of London | Hepatitis b monoclonal antibodies |
| EP0948533A1 (en) * | 1996-12-30 | 1999-10-13 | Innogenetics N.V. | ANNEXIN V-BINDING POLYPEPTIDES DERIVED FROM HBsAg AND THEIR USES |
| US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
| MY133346A (en) | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
| WO2004076677A2 (en) | 2003-02-26 | 2004-09-10 | Institute For Research In Biomedicine | Monoclonal antibody production by ebv transformation of b cells |
| WO2005000899A2 (en) | 2003-06-27 | 2005-01-06 | Biogen Idec Ma Inc. | Modified binding molecules comprising connecting peptides |
| CA2594922A1 (en) * | 2005-01-14 | 2006-07-20 | The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services | Monoclonal antibodies that bind or neutralize hepatitis b virus |
| CN101802197A (zh) | 2007-05-14 | 2010-08-11 | 比奥根艾迪克Ma公司 | 单链FC（ScFc）区、包含其的结合多肽及与其相关的方法 |
| KR20090056537A (ko) * | 2007-11-30 | 2009-06-03 | 주식회사 녹십자 | Ｂ형 간염 바이러스 중화능을 갖는 항체를 유효성분으로포함하는 ｂ형 간염 바이러스 감염의 예방 또는 치료용조성물 |
| PL2350128T3 (pl) | 2008-10-22 | 2015-03-31 | Inst Res Biomedicine | Sposoby wytwarzania przeciwciał z komórek plazmatycznych |
| EP2890403A4 (en) * | 2012-08-30 | 2016-03-09 | Replicor Inc | METHOD FOR THE TREATMENT OF HEPATITIS B AND HEPATITIS D INFECTIONS |
| WO2014072526A1 (en) * | 2012-11-12 | 2014-05-15 | Ruprecht-Karls-Universität Heidelberg | Development of hbv- and/or hdv-susceptible cells, cell lines and non-human animals |
| SG10201806025TA (en) * | 2014-01-16 | 2018-08-30 | Mario Umberto Francesco Mondelli | Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen |
| WO2017059878A1 (en) * | 2015-10-07 | 2017-04-13 | Humabs Biomed Sa | Antibodies that potently neutralize hepatitis b virus and uses thereof |
-
2015
- 2015-10-07 WO PCT/EP2015/001970 patent/WO2017059878A1/en active Application Filing
-
2016
- 2016-10-07 EP EP16779075.7A patent/EP3359564B1/en active Active
- 2016-10-07 AU AU2016334735A patent/AU2016334735B2/en active Active
- 2016-10-07 EP EP20177206.8A patent/EP3753949A1/en active Pending
- 2016-10-07 WO PCT/EP2016/074114 patent/WO2017060504A1/en active Application Filing
- 2016-10-07 CN CN202210187026.6A patent/CN114539392B/zh active Active
- 2016-10-07 KR KR1020187012979A patent/KR20180056777A/ko not_active Application Discontinuation
- 2016-10-07 PL PL16779075T patent/PL3359564T3/pl unknown
- 2016-10-07 DK DK16779075.7T patent/DK3359564T3/da active
- 2016-10-07 CA CA2993745A patent/CA2993745A1/en active Pending
- 2016-10-07 HU HUE16779075A patent/HUE050231T2/hu unknown
- 2016-10-07 SI SI201630896T patent/SI3359564T1/sl unknown
- 2016-10-07 BR BR112018002406-6A patent/BR112018002406A2/pt active Search and Examination
- 2016-10-07 LT LTEP16779075.7T patent/LT3359564T/lt unknown
- 2016-10-07 CN CN202210185497.3A patent/CN114539391A/zh active Pending
- 2016-10-07 CN CN201680055161.8A patent/CN108137675B/zh active Active
- 2016-10-07 PT PT167790757T patent/PT3359564T/pt unknown
- 2016-10-07 US US15/766,703 patent/US10683344B2/en active Active
- 2016-10-07 JP JP2018514962A patent/JP6869968B2/ja active Active
- 2016-10-07 EA EA201890874A patent/EA038301B1/ru unknown
- 2016-10-07 ES ES16779075T patent/ES2813927T3/es active Active
- 2016-10-07 MY MYPI2018700678A patent/MY187161A/en unknown
- 2016-10-07 MX MX2018004127A patent/MX2018004127A/es unknown
-
2018
- 2018-01-25 PH PH12018500199A patent/PH12018500199A1/en unknown
- 2018-02-02 ZA ZA2018/00710A patent/ZA201800710B/en unknown
- 2018-03-25 IL IL258326A patent/IL258326B/en unknown
- 2018-12-12 HK HK18115967.7A patent/HK1256869A1/zh unknown
-
2020
- 2020-04-30 US US16/864,087 patent/US11390664B2/en active Active
- 2020-08-26 CY CY20201100795T patent/CY1123462T1/el unknown
- 2020-08-26 HR HRP20201345TT patent/HRP20201345T1/hr unknown
-
2021
- 2021-04-14 JP JP2021068062A patent/JP7171809B2/ja active Active
-
2022
- 2022-07-18 US US17/867,466 patent/US20230303663A1/en active Pending
- 2022-11-02 JP JP2022175909A patent/JP2023011809A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018002406A2 (pt) | anticorpos que neutralizam potentemente o vírus da hepatite b e usos dos mesmos | |
| BR112018074456A2 (pt) | anticorpos que se ligam especificamente aos epítopos do zika vírus e usos dos mesmos | |
| PH12019550220A1 (en) | Methods for the treatment of subjects having a hepatitis b virus (hbv) infection | |
| ZA202104213B (en) | Antibodies that neutralize hepatitis b virus and uses thereof | |
| EA202091513A1 (ru) | Вакцины против вируса гепатита b (hbv) и их применение | |
| CO2018004321A2 (es) | Anticuerpo que neutraliza el virus respiratorio sincitial humano | |
| BR112017010298A2 (pt) | anticorpos que neutralizam de modo potente vírus da raiva e outros lissavírus e usos dos mesmos | |
| CL2020000467A1 (es) | Anticuerpos multiespecíficos que se unen específicamente a los epítopos del virus del zika y usos de los mismos. | |
| MX2016004063A (es) | Variante de la proteina pcv2 orf2 y particulas similares al virus compuestas por esta. | |
| EA201990010A1 (ru) | Вакцина против вируса инфекционного бронхита | |
| WO2014150822A3 (en) | Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use | |
| BR112022011099A2 (pt) | Tratamento de doenças relacionadas ao vírus da hepatite b | |
| MY163742A (en) | Epitope and its use of hepatitis b virus surface antigen | |
| BR112018007121A2 (pt) | anticorpo ou antígeno de ligação ao fragmento do mesmo, anticorpo humanizado ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucléico isolada, vetor, célula hospedeira, método para preparar o anticorpo ou um antígeno de ligação ao fragmento do mesmo, composição farmacêutica, uso do anticorpo ou um antígeno de ligação ao fragmento do mesmo e método para prevenir ou tratar infecção hbv ou uma doença associada com a infecção hbv | |
| CU20190013A7 (es) | Composiciones de vacunas multivalentes | |
| EA202191147A1 (ru) | Вакцина виб h52 с гетерологичным шиповидным белком | |
| JP2019043937A5 (pt) | ||
| EA202191706A1 (ru) | Антитела, нейтрализирующие вирус гепатита в, и их применение | |
| ECSP18039827A (es) | Anticuerpo que neutraliza el virus respiratorio sincitial humano | |
| TH167679B (th) | โมเลกุลกรดนิวคลีอิกซึ่งเข้ารหัสโปรตีนแกนกลางไวรัสตับอักเสบชนิดบี และโปรตีนแอนติเจนพื้นผิวและวัคซีนซึ่งประกอบรวมด้วยสิ่งเดียวกัน | |
| PL410950A1 (pl) | Immunogenna szczepionka przeciwko wirusowi HCV i/lub HBV | |
| LV14945A (lv) | Ekspresijas sistēma HBc-preS1 vīrusveidīgo daļiņu iegūšanai | |
| PL401359A1 (pl) | Przeciwciala poliklonalne klasy IgY specyficzne wobec bialka gp120 wirusa HIV-1, sposób ich wytwarzania oraz ich zastosowanie |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25G | Requested change of headquarter approved |
Owner name: HUMABS BIOMED SA (CH) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] |